ReviewReviews in endocrine & metabolic disorders2026
Neurocognitive performance and appetite-regulating hormones in obesity with and without eating disorders: A comprehensive review and empirical analysis.
Review in Reviews in endocrine & metabolic disorders, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Obesity and eating disorders (ED) share neurocognitive vulnerabilities involving executive control and reward processing, yet the neuroendocrine–cognitive links underlying their comorbidity remain underexplored. This study synthesizes current evidence on neurocognitive mechanisms in obesity and ED and examines associations between neurocognition and appetite-regulating hormones in clinical groups. A cross-sectional analysis was conducted in 171 women: obesity with ED (OB + ED; n = 43), obesity without ED (OB–ED; n = 70), and healthy controls (HC; n = 58). Neurocognition was assessed using the Conners’ Continuous Performance Test-II (attention/inhibition) and Iowa Gambling Task (decision-making); impulsivity with UPPS-P; fasting ghrelin, insulin, leptin, and LEAP2 were measured. OB + ED showed higher omission errors than HC (p<0.001, d = 0.40) and higher commission errors than OB–ED (p=0.035, d = 0.46), indicating greater attentional lapses and impulsive responding. Iowa Gambling performance did not differ overall, but OB + ED outperformed OB–ED in mid-learning phases, suggesting enhanced feedback sensitivity. Impulsivity profiles diverged, with OB + ED showing higher Lack of Premeditation. Endocrine profiles revealed higher LEAP2 and lower ghrelin in both obesity groups versus HC, with insulin elevated in OB–ED. Structural equation modeling indicated leptin uniquely predicted attentional lapses, slower reaction times, and impulsivity traits, with downstream links to BMI and decision-making. These findings support integrated models in which leptin-linked neuroendocrine dysregulation intersects with attention, decision-making, and impulsivity in obesity and ED comorbidity, highlighting targets for mechanistically informed, combined metabolic–cognitive interventions.
Indexed as
Identifiers
41894102What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.